AstraZeneca to acquire EsoBiotec for ~$1B

Shots:AstraZeneca to acquire EsoBiotec, which will operate as AstraZeneca’s subsidiary, while maintaining its operations in Belgium to advance cell therapy As per the deal, AstraZeneca will acquire all outstanding equity of EsoBiotec on a cash & debt-free basis for ~$1B, incl. $425M upfront at closing & ~$575M in development & regulatory milestones; closing…

ByRidhi RastogiMarch 18, 2025

News

Neurotech Pharmaceuticals Reports the US FDA Approval for Encelto to treat Macular Telangiectasia Type 2

Shots:The US FDA has approved Encelto (revakinagene taroretcel-lwey) to treat macular telangiectasia type 2 (MacTel); commercially available in the US by Jun 2025 Approval was based on P-III trial data demonstrating reduced macular photoreceptor loss for ~24mos. post-implantation Encelto (intravitreal implant) utilizes an encapsulated cell therapy tech to continuously deliver ciliary neurotrophic…

ByRidhi RastogiMarch 7, 2025

VIEWPOINTS

Mark Cobbold and Carsten Linnemann Share Insights on Neogene Therapeutics’ Acquisition

Shots:Carsten gave the details of the agreement with Neogene Therapeutics to bring cell therapies to patients with solid tumors through Neogene’s next-generation T-cell receptor therapies. He also talked about Neogene’s TCR discovery platformMark spoke about how this acquisition provides AstraZeneca with a unique opportunity to bring innovative science and leading experts in T-cell…

BySenior EditorMay 4, 2023

EVENTS

Pharma Tech Conclave 2023

Chitkara University and DeepSynergy presents the Pharma Tech Conclave 2023. The conference will be held on 3rd Mar 2023 from 9:00 am to 5:00 pm IST at the Chitkara College of Pharmacy, Chitkara University, Chandigarh. The global pharmaceutical industry is undergoing transformational changes due to advancements in technological innovations that aim to fundamentally alter how patients…

BySenior EditorFebruary 22, 2023

INSIGHTS+

Disease of the Month: Cerebral Palsy

INTRODUCTIONCerebral Palsy is a group of neurological disorders which affect motor and developmental skills. It causes disability in muscle tone, movement, balance, and posture. It is the most common motor disability in childhood with an estimated prevalence ranging from 1-4 per 1,000 live births. The incidence of CP is more in preterm or low…

BySenior EditorOctober 18, 2022

VIEWPOINTS

PharmaShots Interview: Indapta’s Mark Frohlich Shares Insights on the $50M Series A Financing

In an interview with PharmaShots, Mark Frohlich, CEO at Indapta Therapeutics shared his views on the closing of $50M A financing and how it will advance its cell therapy drug developmentShots:The company closes $50M A financing, co-led by RA Capital Management, LP, Vertex Ventures HC, and Bayer AG with Mark Frohlich appointed as M.D.,…

BySenior EditorMay 23, 2022

AstraZeneca to acquire EsoBiotec for ~$1B

Neurotech Pharmaceuticals Reports the US FDA Approval for Encelto to treat Macular Telangiectasia Type 2

Mark Cobbold and Carsten Linnemann Share Insights on Neogene Therapeutics’ Acquisition

Pharma Tech Conclave 2023

Disease of the Month: Cerebral Palsy

PharmaShots Interview: Indapta’s Mark Frohlich Shares Insights on the $50M Series A Financing

Contact US

OUR INFORMATION

FOLLW US

AstraZeneca to acquire EsoBiotec for ~$1B

Neurotech Pharmaceuticals Reports the US FDA Approval for Encelto to treat Macular Telangiectasia Type 2

Mark Cobbold and Carsten Linnemann Share Insights on Neogene Therapeutics’ Acquisition

Pharma Tech Conclave 2023

Disease of the Month: Cerebral Palsy

PharmaShots Interview: Indapta’s Mark Frohlich Shares Insights on the $50M Series A Financing

FOLLW US

Sign Up to Our Newsletter